spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  herpes zoster 

 HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals
 HSMN NewsFeed - 24 Aug 2021
European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2020
CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Sep 2020
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Dec 2017
FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Nov 2017
Johnson & Johnson Vision Announces Series of Product Milestones and Launches Across Portfolio at American Academy of Ophthalmology 2017 Meeting
Devices Ophthalmology Product Launch
 HSMN NewsFeed - 9 Nov 2017
NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 5 Sep 2017
Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years with Maximum of Only 20 Days Oral Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Aug 2017
European Commission Grants Approval for Mavenclad (Cladribine Tablets)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 16 Jun 2017
New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
Biopharmaceuticals
 HSMN NewsFeed - 26 Apr 2017
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Dec 2016
ContraVir Appoints Business Development Executive Tamar Howson to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2016
ContraVir Completes Merger with Ciclofilin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Apr 2016
Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 31 Mar 2016
ContraVir Pharmaceuticals Appoints John Cavan as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Dec 2015
Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA(TM) (bendamustine hydrochloride) Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Jun 2014
Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 May 2014
Spinifex Pharmaceuticals Strengthens Scientific Advisory Board (SAB) with Experts in Chronic Pain
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Apr 2014
Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 3 Jan 2014
RegeneRx Receives Orphan Drug Designation for Tβ4 in the Treatment of Neurotrophic Keratopathy
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jul 2013
Pfizer Provides Update on Global Regulatory Approvals and Launches of XELJANZ(R) (tofacitinib citrate) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Mar 2013
XELJANZ(R) (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Mar 2013
Merck Announces Appointment of Roger M. Perlmutter, M.D., Ph.D., As President of Merck Research Laboratories; Peter S. Kim, Ph.D., to Retire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Nov 2012
U.S. Food and Drug Administration Approves Pfizer’s XELJANZ(R) (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Jun 2012
GSK and XenoPort Receive FDA Approval for Horizant(R) for Postherpetic Neuralgia
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Nov 2011
FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE(R) in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Sep 2011
Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 23 Aug 2011
Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Mar 2011
FDA Expands Indication for ZOSTAVAX(R), Merck’s Shingles Vaccine, to Include Adults Ages 50 to 59
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2010
EpiCept Receives Orphan Drug Designation for EpiCept NP-1 in U.S.
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Jun 2009
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 24 Mar 2009
Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Oct 2008
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2008
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 21 May 2008
American Academy of Dermatology Issues New Guidelines for the Management of Psoriasis and Psoriatic Arthritis
Dermatology
 HSMN NewsFeed - 15 May 2008
CDC Recommends ZOSTAVAX(R), Merck's Shingles Vaccine, for All Appropriate Adults Aged 60 and Older
Biopharmaceuticals
 HSMN NewsFeed - 24 Mar 2008
Depomed Doses First Patient in New Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
Biopharmaceuticals
 HSMN NewsFeed - 22 Feb 2008
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Feb 2008
EpiCept Announces Encouraging Results of Phase II Trial for NP-1 Cream in Diabetic Peripheral Neuropathy
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2007
Shareholders Approve Inhibitex Acquisition of FermaVir
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Jul 2007
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2007
Critical Biologics Appoints Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Apr 2007
FermaVir Pharmaceuticals, Inc. Signs Definitive Agreement to Be Acquired by Inhibitex, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Apr 2007
Inhibitex Signs Definitive Agreement to Acquire FermaVir Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Apr 2007
EpiCept Initiates Two Phase IIb Trials with NP-1
Biopharmaceuticals
 HSMN NewsFeed - 2 Feb 2007
Valtrex (valacyclovir) - US Patent Litigation Update
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 1 Feb 2007
Ranbaxy Receives Final FDA Approval to Manufacture and Market Valacyclovir HCl Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 4 Dec 2006
Janus Pharmaceuticals Inc. Announces Successful Phase II Study in Shingles
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2006
WellPoint to Cover Varicella Zoster Virus, or Shingles Vaccine
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 29 Sep 2006
TAP Enters Into Co-Promotion Agreement for Famvir(R)
Biopharmaceuticals
 HSMN NewsFeed - 5 Sep 2006
EpiCept Announces Results of European Phase III Trial for LidoPAIN(R) SP
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 28 Jul 2006
FDA Approves Supplemental New Drug Application for Antiviral Treatment Famvir(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jun 2006
NeurogesX Completes Enrollment in Pivotal Phase 3 Postherpetic Neuralgia Trial
Biopharmaceuticals
 HSMN NewsFeed - 26 May 2006
FDA Approves ZOSTAVAX(R), Merck's New Vaccine for Prevention of Shingles in Adults Age 60 and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 May 2006
Depomed Finalizes Phase III Clinical Trial Protocol for Gabapentin GR(TM)
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 3 Mar 2006
FermaVir Appoints Finance and Biotech Industry Executive Frederick Larcombe as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2006
David Peralta Joins NanoBio(R) as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jan 2006
Depomed Announces Positive Results of Phase II Clinical Trial for Gabapentin GR(TM) in Postherpetic Neuralgia
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 17

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 17 additional stories matching:
herpes zoster
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.